Twin pregnancy consisting of 46, XY heterozygous complete mole coexisting with a live fetus

被引:13
作者
Kahsimura, Y
Tanaka, M
Harada, N
Shinmoto, M
Morishita, T
Morishita, H
Kashimura, M
机构
[1] Kyushu Rosai Hosp, Dept Obstet & Gynecol, Minami Ku, Kitakyushu, Fukuoka 8000296, Japan
[2] Kyushu Med Sci Nagasaki Lab, Nagasaki, Japan
[3] Morishita Ob & Gyn Clin, Fukuoka, Japan
[4] Univ Occupat & Environm Hlth, Kitakyushu, Fukuoka 807, Japan
关键词
D O I
10.1053/plac.2000.0613
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Complete hydatidiform mole and coexistent fetus (CMCF) is a rare occurrence and is associated with an increased risk of persistent gestational trophoblastic diseases. The aim of this study was to reveal a potential risk, factor and to determine optimum management of CZ;ICF cases. Molar tissues are c! cytogenetically divided into two types, homozygous and heterozygous. The molar tissue of our case showed a 46, XY heterozygous complete mole. Genomic DNA was analyzed by the polymerase chain reaction using sers of unlabelled forward and Cy-5-labelled reverse primers for DNA marker loci. Tl;e patient developed persistent trophoblastic disease (PTD) with lung metastasis. Since 1980 there have been 13 reports (including our case) that cytogenetically revealed CMCF and clarified the clinical outcome. Wine of the 16 CMCF cases before 21 weeks of gestation and seven of the 12 CR:LCF cases after 22 weeks of gestation developed PTD. The incidence of PTD from CMCF was not related to the gestational age at termination or delivery. There were 10 case reports that analyzed the zygosity of a mole heterozygous or homozygous. Two of six homozygous and three of font heterozygous moles in CMCF cases developed PTD. A heterozygous mole is thought to be a high risk factor. for the incidence of PTD. Cytogenetic study is clinically useful for the optimum management of CMCF cases. (C) 2001 Harcourt Publishers Ltd.
引用
收藏
页码:323 / 327
页数:5
相关论文
共 32 条
[21]  
OHAMA K, 1985, HIROSHIMA J MED SCI, V34, P371
[22]   DISPERMIC ORIGIN OF XY HYDATIDIFORM MOLES [J].
OHAMA, K ;
KAJII, T ;
OKAMOTO, E ;
FUKUDA, Y ;
IMAIZUMI, K ;
TSUKAHARA, M ;
KOBAYASHI, K ;
HAGIWARA, K .
NATURE, 1981, 292 (5823) :551-552
[23]   HYDATIDIFORM MOLE IN A TRIPLET PREGNANCY FOLLOWING GONADOTROPIN THERAPY [J].
OHMICHI, M ;
TASAKA, K ;
SUEHARA, N ;
MIYAKE, A ;
TANIZAWA, O .
ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA, 1986, 65 (05) :523-524
[24]  
SEKI T, 1982, ACTA OBSTET GYNEC JP, V34, P2221
[25]  
SOYAL M, 1996, ARCH GYNECOL OBSTET, V259, P41
[26]  
STELLER MA, 1994, J REPROD MED, V39, P147
[27]  
VEJERSLEV L O, 1991, Obstetrical and Gynecological Survey, V46, P577
[28]   HYDATIDIFORM MOLE - CYTOGENETIC MARKER ANALYSIS IN TWIN GESTATION [J].
VEJERSLEV, LO ;
DUEHOLM, M ;
NIELSEN, FH .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1986, 155 (03) :614-617
[29]   ANDROGENESIS AS A CAUSE OF HYDATIDIFORM MOLE [J].
WAKE, N ;
TAKAGI, N ;
SASAKI, M .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1978, 60 (01) :51-57
[30]   THE PROPENSITY TO MALIGNANCY OF DISPERMIC HETEROZYGOUS MOLES [J].
WAKE, N ;
FUJINO, T ;
HOSHI, S ;
SHINKAI, N ;
SAKAI, K ;
KATO, H ;
HASHIMOTO, M ;
YASUDA, T ;
YAMADA, H ;
ICHINOE, K .
PLACENTA, 1987, 8 (03) :319-326